Clinical features and blood iron metabolism markers in children with beta-propeller protein associated neurodegeneration
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články
PubMed
32811771
DOI
10.1016/j.ejpn.2020.07.010
PII: S1090-3798(20)30154-9
Knihovny.cz E-zdroje
- Klíčová slova
- Beta-propeller protein-associated neurodegeneration, Neurodegeneration with brain iron accumulation WDR45, BPAN, Targeted gene panel sequencing,
- MeSH
- biologické markery krev MeSH
- dítě MeSH
- epilepsie krev genetika metabolismus MeSH
- fenotyp MeSH
- lidé MeSH
- mentální retardace krev genetika metabolismus MeSH
- neurodegenerativní nemoci krev genetika metabolismus MeSH
- pohybové poruchy krev genetika metabolismus MeSH
- poruchy metabolismu železa krev genetika metabolismus MeSH
- transportní proteiny genetika MeSH
- železo krev MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- biologické markery MeSH
- transportní proteiny MeSH
- WDR45 protein, human MeSH Prohlížeč
- železo MeSH
BACKGROUND: Neurodegeneration with brain iron accumulation constitutes a group of rare progressive movement disorders sharing intellectual disability and neuroimaging findings as common denominators. Beta-propeller protein-associated neurodegeneration (BPAN) represents approximately 7% of the cases, and its first signs are typically epilepsy and developmental delay. We aimed to describe in detail the phenotype of BPAN with a special focus on iron metabolism. MATERIAL AND METHODS: We present a cohort of paediatric patients with pathogenic variants of WD-Repeat Domain 45 gene (WDR45). The diagnosis was established by targeted panel sequencing of genes associated with epileptic encephalopathies (n = 9) or by Sanger sequencing of WDR45 (n = 1). Data on clinical characteristics, molecular-genetic findings and other performed investigations were gathered from all participating centres. Markers of iron metabolism were analysed in 6 patients. RESULTS: Ten children (3 males, 7 females, median age 8.4 years) from five centres (Prague, Berlin, Vogtareuth, Tubingen and Cologne) were enrolled in the study. All patients manifested first symptoms (e.g. epilepsy, developmental delay) between 2 and 31 months (median 16 months). Seven patients were seizure-free (6 on antiepileptic medication, one drug-free) at the time of data collection. Neurological findings were non-specific with deep tendon hyperreflexia (n = 4) and orofacial dystonia (n = 3) being the most common. Soluble transferrin receptor/log ferritin ratio was elevated in 5/6 examined subjects; other parameters of iron metabolism were normal. CONCLUSION: Severity of epilepsy often gradually decreases in BPAN patients. Elevation of soluble transferrin receptor/log ferritin ratio could be another biochemical marker of the disease and should be explored by further studies.
Children's Hospital Amsterdamer Straße Kliniken der Stadt Köln Cologne Germany
Department of Neuropediatrics University Children's Hospital Tübingen Germany
Epilepsy Center Paediatric Neurology DRK Kliniken Berlin Westend Berlin Germany
Citace poskytuje Crossref.org
Cerebral Iron Deposition in Neurodegeneration
A comprehensive phenotypic characterization of a whole-body Wdr45 knock-out mouse